Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Takeda plans layoffs in R&D reorganization

by Jean-François Tremblay
August 8, 2016 | A version of this story appeared in Volume 94, Issue 32

Takeda Pharmaceutical will eliminate an unspecified number of jobs as part of an R&D revamp. The company says it plans to centralize research in the U.S. and Japan, suggesting that its R&D center in the U.K., which employs 400, is threatened. Takeda’s research center in Shonan, Japan, on which it recently spent $1.8 billion, will concentrate on the central nervous system and regenerative medicine. The company also will continue to research vaccines, gastroenterology, and oncology. The layoffs and related restructuring will cost $740 million over the next two years, the firm anticipates.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.